Navigation Links
Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
Date:10/17/2007

omplementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether the company will successfully enroll 80 matched, related stem cell transplant donor/recipient pairs or 80 additional recipients in a timely manner, if at all; whether the CMV vaccine will achieve the safety and efficacy endpoints in the Phase 2 trial for stem cell transplant donors and/or recipients, including whether the favorable interim safety data are predictive of safety data for the full trial; whether the company will expand development of a CMV vaccine to address prevention of congenital disease; whether the vaccine will induce both antibody and cellular immune responses; whether the vaccine will prevent clinically significant CMV levels; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contacts: Investors: Media:

Alan R. Engbring Susan Neath

Vical Incorporated Porter Novelli Life Sciences

(858) 646-1127 (619) 849-6007

Website:

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 The U.S. Food and Drug ... today voted 12 yes, 4 no, and 1 abstention ... observed risks to support the use of CRESTOR® (rosuvastatin ... Men greater than or equal to 50 years, women ... Fasting LDL < 130 mg/dL; hsCRP greater than or ...
(Date:12/15/2009)... -- Medical researchers with EDP Biotech Corporation (EDP) ... technology for a simple blood test to detect ... success of its pre-clinical trials for the ColoMarker(TM) ... biomarker, CA11-19, and all aspects of its use. ... detect colon cancer in its earliest, most curable ...
(Date:12/15/2009)... -- Certified healthcare providers who have already immunized ... H1N1 flu virus may now offer the vaccine ... Health announced today. ,, Pennsylvania is expanding ... 3.2 million doses of vaccine have been allocated ... in the priority groups. ,, "Many certified providers ...
Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research 26 Development 13756 1Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research 26 Development 13756 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research 26 Development 13756 3CBI Announces Multi Stakeholder Collaboration Panel at Upcoming Effective Oncology Benefit Management Forum 55824 1CBI Announces Multi Stakeholder Collaboration Panel at Upcoming Effective Oncology Benefit Management Forum 55824 2New Non Drowsy CLARITIN 28R 29 12 Hour Gets Allergy Sufferers Through Their Busy Day 55822 1New Non Drowsy CLARITIN 28R 29 12 Hour Gets Allergy Sufferers Through Their Busy Day 55822 2New Non Drowsy CLARITIN 28R 29 12 Hour Gets Allergy Sufferers Through Their Busy Day 55822 3
... June 1, 2007 – Thallion Pharmaceuticals Inc.,(TSX: TLN) ... clinical trial investigating ECO-4601 in advanced cancer,patients was ... American,Society of Clinical Oncology (ASCO) Annual Meeting in ... of the study, 14,patients (ten colorectal, two ovarian, ...
... trial confirms that more patients,are alive today due ... analysis tracking,the outcome of patients with aggressive non-Hodgkin's ... therapy MabThera,(rituximab) over seven years ago has revealed ... pivotal phase III study has shown,that over half ...
Other Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 2MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 3MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 4
(Date:12/15/2009)... of the U.S. Senate to allow importation of ... more effective direct bulk purchasing of prescription drugs, ... industry controls the health reform debate, according Consumer ... Dorgan (D-ND) was a relatively modest proposal, far ... to directly negotiate discounts with drug manufacturers," said ...
(Date:12/15/2009)... SUNNYVALE, Calif., Dec. 15 Palo Alto ... Shinshu University has deployed its PA-4000 Series next-generation ... network and for enhanced visibility and control over ... University is a Japanese national university with eight ... in 1949 by integrating a number of academic ...
(Date:12/15/2009)... where all couples of reproductive age were evaluated, Italian ... The number of children born with cystic fibrosis decreases ... mutation carriers increases, a new study finds. , CF ... northeast Italy for many years. Since the 1990s, the ... number of infants born with CF. , Two different ...
(Date:12/15/2009)... cancer tests promised but not delivered ,, ... calls on Congress to ensure that healthcare reform ... currently required of insurance companies in 37 states. ... those segments of the population and individuals who ... men and men who have a family history ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., will ... "it doesn,t matter whether there,s a public option. The ... option - give government authority over how your doctor ... social agenda by shifting billions of dollars from Medicare ... and local politicians." ,, Betsy McCaughey is ...
Breaking Medicine News(10 mins):Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2
... as annoying as a sore throat with the exception of ... is just moments away.// ,The American Academy of ... over-the-counter pain killer like acetaminophen, ibuprofen or naproxen. ,* Make ... or hard candy. ,* Gargle with salt water as many ...
... associated with spinal tumors has been developed by a ... vertebrae is a common feature in 5 to 10 ... ,Wade Wong, D.O.F.A.C.R, UCSD professor of radiology, ... spinal tumors from 28 patients before repairing the spine ...
... breakthrough in the field of nanotechnology, researchers have ... an anticoagulant. These blood compatible could ,revolutionize medical ... for renal failure patients. ,Furthermore, these ... applications that are ,not foreseen at the moment. ...
... may actually lull the consumer into a false sense ... case//. The European commission has got its act together ... labeling of sun lotions and its allied products. ... cues by captivatingly labeling a total protection message are: ...
... marathon kid of Orissa, declared that his health is normal. ... check up after he ran an astounding 65km earlier this ... Hospital at Bhubaneswar for a medical check up on the ... that coach Biranchi Das was exploiting the boy for his ...
... of PMS, those who have a caring and compassionate husband ... a new study. ,Time and over again, hormonal ... lethargy and pain associated with premenstrual syndrome or PMS. This ... for their wives can make matters worse. ,Women ...
Other Medicine News:Health News:Novel Technique To Revolutionize Treatment Of Spinal Tumors 2Health News:Heparin Based Nanoscale Materials Developed For Dialysis Treatment 2Health News:Marathon Kid Budhia’s Health Not Compromise 2Health News:Supportive Husbands Can Help Ease PMS 2
Inquire...
... Multifocal IOL was designed to provide a ... glasses in most situations. While distance vision ... to that of a single vision monofocal ... and about 19 in 20 people with ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... Zeus Scientific, Inc. Measles test ... qualitative and quantitative detection of ... by the indirect fluorescent antibody ... determine or confirm recent infection ...
Medicine Products: